David Kirske Sells 8,543 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CFO David Kirske sold 8,543 shares of X4 Pharmaceuticals stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $4.26, for a total value of $36,393.18. Following the completion of the sale, the chief financial officer owned 167,750 shares in the company, valued at approximately $714,615. This represents a 4.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

X4 Pharmaceuticals Trading Down 12.4%

Shares of X4 Pharmaceuticals stock traded down $0.58 during midday trading on Wednesday, reaching $4.09. 806,979 shares of the company’s stock traded hands, compared to its average volume of 536,639. The company has a debt-to-equity ratio of 0.45, a quick ratio of 9.98 and a current ratio of 10.18. The company has a market cap of $385.77 million, a PE ratio of -0.90 and a beta of 0.34. The stock has a 50 day moving average of $4.09 and a 200-day moving average of $3.93. X4 Pharmaceuticals, Inc. has a 12 month low of $1.35 and a 12 month high of $4.83.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%. The business had revenue of $2.71 million for the quarter, compared to the consensus estimate of $3.20 million. As a group, equities analysts expect that X4 Pharmaceuticals, Inc. will post -0.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of XFOR. Bank of America Corp DE lifted its position in X4 Pharmaceuticals by 20.3% during the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after acquiring an additional 22,485 shares during the period. Rhumbline Advisers grew its holdings in X4 Pharmaceuticals by 5.4% in the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after purchasing an additional 9,690 shares during the period. Jane Street Group LLC increased its stake in shares of X4 Pharmaceuticals by 112.5% during the second quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock valued at $185,000 after purchasing an additional 51,544 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of X4 Pharmaceuticals by 77.0% during the third quarter. Vanguard Group Inc. now owns 410,485 shares of the company’s stock valued at $1,404,000 after purchasing an additional 178,593 shares in the last quarter. Finally, Rosalind Advisors Inc. purchased a new position in shares of X4 Pharmaceuticals during the third quarter valued at approximately $5,283,000. 72.03% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on XFOR shares. Weiss Ratings raised shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Guggenheim initiated coverage on X4 Pharmaceuticals in a research report on Monday, March 9th. They set a “buy” rating and a $12.00 price objective on the stock. Wall Street Zen upgraded X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Finally, Leerink Partners assumed coverage on X4 Pharmaceuticals in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 target price for the company. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.38.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.